Stem-cell-based, tissue engineered tracheal replacement in a child: a 2-year follow-up study.

The article focuses on a study which shows that a stem-cell-based, tissue-engineered tracheal transplant is a potential therapeutic option for patients. It mentions that patients treated with autologous stemcell-derived transplants do not need immunosuppression. It reflects that normal airway and lung function, high quality of life, and the elimination of the need for repeated surgical interventions were the end-points of a tracheal replacement in children.